View Older Stories View More Recent Stories
-
Roth Capital Cuts Price Target on Cytori Therapeutics (CYTX) Following 2Q Earnings Report
-
Roth Capital Cuts Price Target on Curis (CRIS) Following 2Q Results
-
Roth Capital Starts Omeros Corp. (OMER) at Buy
-
Roth Capital Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
-
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering
-
Roth Capital Cuts Price Target on Tangoe (TNGO) to $16 Following EPS Miss
-
Roth Capital Upgrades NVIDIA (NVDA) to Buy
-
Pixelworks (PXLW) Prices 3.25M Common Stock Offering at $4.75/Share
-
Pixelworks Announces Details of Common Stock Offering of 3.25 Million Shares with Gross Proceeds of $15.4 Million
-
Roth Capital Upgrades Planar Systems (PLNR) to Buy
-
Robust Margins Propel Plug Power (PLUG) to Mixed Q2 Results; Roth Affirms at 'Neutral'
-
Pixelworks (PXLW) to Offer Common Stock
-
Pixelworks Announces Public Offering of Common Stock
-
Roth Capital Cuts Price Target on Zumiez, Inc. (ZUMZ) Following Quarter Results
-
Roth Capital Cuts Price Target on Power Solutions (PSIX) to $75 Following In-Line EPS
-
Roth Capital Raises Price Target on Manitex Int'l (MNTX) to $8 Following 2Q15
-
Roth Capital Raises Price Target on PowerSecure (POWR) Following EPS Beat
-
Roth Capital Cuts Price Target on Apricus Biosciences (APRI) to $3 Following 2Q15
-
Roth Capital Cuts Price Target on Apricus Biosciences (APRI) to $3 Following 2Q15
-
SodaStream (SODA) Bullish Stance Reiterated at Roth Capital; Sees Gradual Recovery in 2nd-Half
-
Roth Remains Positive on SolarCity (SCTY) Following Q2 Results, M&A Outlook; Affirms at 'Buy'
-
Roth Capital Upgrades RSP Permian, Inc. (RSPP) to Buy
-
Sapiens International (SPNS) PT Bumped to $13 at Roth Capital Amid Strong Results
-
Notable Analyst Rating Changes 8/5: (MRVL) (JCP) (LXK) Upgraded; (AAPL) (ADSK) (VSH) Downgraded
-
Roth Capital Cuts Price Target on ZAGG, Inc. (ZAGG) Following 2Q EPS Beat
-
Roth Capital Downgrades TriMas Corp. (TRS) to Neutral
-
Roth Capital Raises Price Target on Masimo Corp. (MASI) to $46 Following 2Q Results and Guidance
-
Roth Capital Assumes Ideal Power (IPWR) at Buy
-
Roth Capital Downgrades Orion Energy Systems (OESX) to Neutral
-
Intec Pharma (NTEC) IPO Opens Flat
-
Intec Pharma (NTEC) Prices 5.03M Ordinary Share IPO at $6/Share
-
Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering
-
Roth Capital Upgrades Delta Apparel (DLA) to Buy
-
Roth Capital Affirms TriMas (TRS) at 'Buy' Following Horizon (HZN) Spin; Short-Term Headwinds Mask Robust Potential
-
Roth Capital Raises Price Target on Web.com Group (WWWW) to $28 Following 2Q15 Results
-
Roth Capital Downgrades GP Strategies (GPX) to Neutral
-
Roth Capital Starts General Employment Enterprises (JOB) at Buy
-
Flamel Technologies (FLML) PT Lifted to $30 at Roth Capital Despite 'Noisy' Quarter
-
Roth Affirms Sunesis (SNSS) at 'Sell' Following Q2 Report; Risk of Restructuring Remains
-
Clinton Group Sends Letter To Sphere 3D Board Of Directors
-
ICON — ICONIX INVESTORS ALERT: Lieff Cabraser Reminds Investors of Upcoming Deadline in Class Action Litigation
-
Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors
-
Ligand Pharma (LGND) Becomes 'Value Play' as Viking (VKTX) Advances VK2809 - Roth Capital
-
Roth Capital Remains Positive on Galena Biopharma (GALE) Following Zuplenz Launch
-
Roth Capital Raises Price Target on Lemaitre Vascular, Inc. (LMAT) to $14 Following 2Q Earnings
-
Trinity Biotech (TRIB) PT Lowered to $20 at Roth Capital
-
Roth Capital Starts Tracon Pharmaceuticals (TCON) at Buy
-
RedHill Biopharma Reports Results for the Second Quarter of 2015
-
Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock
-
Roth Capital Positive on Regeneron (REGN) Following 'Impressive' Deal with Sanofi (SNY)'; Affirms at 'Buy'

